Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the final active treatment in study JADV (NCT01710358), JADZ (NCT01711359), JADX (NCT01721057), JADW (NCT01721044), JADA (NCT01185353) or JAGS (NCT02265705)~Exclusion Criteria:~* Have significant uncontrolled cerebro-cardiovascular (eg, myocardial infarction \[MI\], unstable angina, unstable arterial hypertension, severe heart failure, or cerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neuropsychiatric disorders, or abnormal laboratory values that developed during a previous baricitinib study that, in the opinion of the investigator, pose an unacceptable risk to the participant if investigational product continues to be administered~* Have a known hypersensitivity to baricitinib or any component of this investigational product~* Had investigational product permanently discontinued at any time during a previous baricitinib study~* Had temporary investigational product interruption at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for participation in the study~* Have any other condition that, in the opinion of the investigator, renders the participant unable to understand the nature, scope, and possible consequences of the study or precludes the participant from following and completing the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 milligram (mg) Baricitinib (Type: EXPERIMENTAL): 4 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
- 2 mg Baricitinib (Type: EXPERIMENTAL): 2 mg Baricitinib administered orally once daily.~Participants received baricitinib doses according to the dose received at the completion of the originating study. Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
- 2 mg Baricitinib Step-down (Type: EXPERIMENTAL): 2 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.
- 4 mg Baricitinib Step-down (Type: EXPERIMENTAL): 4 mg Baricitinib administered orally once daily in the 96-week Step-down period.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete